LY3962673 for KRAS G12D-mutated solid tumors - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.

¿Cuál es la Condición que se está estudiando?

Solid Tumors with KRAS G12D Mutation

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with a solid tumor form of cancer
Have disease that is inoperable, advanced, or metastatic
The tumor tests positive for a KRAS G12D mutation

For more information, contact the study team at dana.a.warren@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Take the study drug by mouth once or twice every day
Depending on which arm of the study you are in, you may also get standard anti-cancer drugs every 1 to 2 weeks
Hágase biopsia del tumor
Give blood and urine samples
Realice tomografías computarizadas o resonancias magnéticas de manera regular.